JAZZ · Jazz Pharmaceuticals PLC
Price
Snapshot
50 fields · last close| Market Cap | $16.02B |
| P/E | 17.03 |
| Float | 60.69M |
| Beta | 0.37 |
| Volatility | 9.4% |
| Exchange | NASDAQ |
| Sector | Pharmaceuticals |
| Cap tier | Large cap |
| Macro sensitivity | Low |
| Clavix score | 80 |
| Price | 246.81 |
| Change | −0.02% |
| Prev Close | 246.85 |
| Open | 246.00 |
| Day Low | 244.75 |
| Day High | 249.00 |
| Avg Vol | 1 |
| Avg $ Vol | $359.5M |
| 52W High | 266.38 |
| 52W Low | 123.88 |
| 52W Pos | 86.3% |
| From High | −7.34% |
| From Low | +99.23% |
| Max DD 1Y | −11.42% |
| Spread | 0.10% |
| Liquidity | Normal |
| SMA 20 | −1.17% |
| SMA 50 | −0.83% |
| SMA 200 | +20.10% |
| RSI (14) | 47.4 |
| Vol 30D | 29.1% |
| Vol 90D | 30.3% |
| 1Y Range | 124–266 |
| Daily bars | 507 |
| Perf Week | +0.93% |
| Perf Month | −3.83% |
| Perf Quarter | +3.45% |
| Perf Half Y | +35.60% |
| Perf Year | +92.79% |
| Perf YTD | +42.54% |
| Prev Day | −0.02% |
| Clavix | A- |
| Debt / Eq | 1.24 |
| Curr Ratio | 1.86 |
| Int Cover | 5.3× |
| FCF Margin | 32.2% |
| Rev Growth | +15.6% |
| Profit | Unprofitable |
| Leverage | Moderate |
| Sector rank | 5 / 15 |
Clavix risk grade
regraded every trading dayJAZZ grades A-, 80 of 100. Steadiest on Macro Resilience (68), most exposed on News Sentiment (62, mixed). 3 of the 4 weighted dimensions sit above the Pharmaceuticals median. Ranks 5 of 15 in Pharmaceuticals by Clavix score.
How rough the ride is
| JAZZ | Pharmaceuticals median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 0.37 | 0.43 |
| Volatilityannualized | 9.4% | 10.7% |
| Max drawdown, past yearworst peak-to-trough fall | −11.4% | — |
| Typical daily movemedian absolute daily change | 1.02% | — |
| Days beyond ±3%of the last 252 sessions | 218% | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| JAZZ | Pharmaceuticals median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 0.37 | 0.43 |
| Macro sensitivityrate, dollar and credit exposure bucket | Low | Low67% of 15 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Pharmaceuticals names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| JAZZ | |
|---|---|
| 1 week | +0.9% |
| 1 month | −3.8% |
| Year to date | +42.5% |
| 1 year | +92.8% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| JAZZ | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 30since 11 Aug |
| Average score0 most bearish, 100 most bullish | 77 |
| Bullish · bearisharticles above 60 · below 40 | 28 · 0 |
| Directionarticles whose tone is improving vs worsening | 28 ↑ 0 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 15 Pharmaceuticals names Clavix covers; the tick is the sector median.
Growth
| JAZZ | |
|---|---|
| Revenue growthyear over year | +15.6% |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Pharmaceuticals median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Against Pharmaceuticals
15 companies| Metric | JAZZ | Sector spread | Median |
|---|---|---|---|
| Beta | 0.37 | 0.43 | |
| Volatility | 9.4% | 10.7% | |
| Debt / equity | 1.24 | 0.94 | |
| Current ratio | 1.86 | 1.86 | |
| FCF margin | 32.2% | 19.9% | |
| Interest coverage | 5.3× | 5.9× |
Recent news
most recent scored articles · the chip is the article’s score · click to openJazz Pharmaceuticals reported that its drug Ziihera, given with chemotherapy, helped patients live longer than the standard treatment trastuzumab plus chemotherapy in a late-stage (Phase 3) trial called HERIZON-GEA-01, with results now reaching statistical significance after a prior interim look had favored Ziihera but fell short.
Jazz Pharmaceuticals' stock rose after updated results from its HERIZON-GEA-01 study showed that Ziihera-based treatment regimens helped patients with HER2-positive gastroesophageal adenocarcinoma (a stomach cancer driven by a specific growth-promoting protein) live longer when used as a first-line therapy, with the survival benefit reaching statistical significance.
Jazz Pharmaceuticals shares rose. No specific catalyst was identified.ents with HER2-positive gastroesophageal adenocarcinoma (a stomach and lower-esophagus cancer marked by a specific surface protein) live longer, with the survival benefit unlikely to be due to chance.
Jazz Pharmaceuticals rose 2.5% after announcing that its drug Ziihera, when combined with chemotherapy, met the main goal of a late-stage trial in patients with advanced gastroesophageal adenocarcinoma (a type of stomach/esophageal cancer), showing a statistically significant improvement in how long patients lived.
Jazz Pharmaceuticals announced plans for a private offering of $1.0 billion in exchangeable senior notes due 2032, with buyers also having the option to purchase up to an additional $150 million. The notes, issued by its subsidiary Jazz Investments I Limited and guaranteed by Jazz Pharmaceuticals, can be exchanged under certain conditions into cash and/or Jazz ordinary shares. The company also announced concurrent ordinary share repurchases.
Nearest peers by size
Pharmaceuticals| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| VTRS | Viatris Inc | B+ | $20.71B | — | 0.92 | Compare |
| ELAN | Elanco Animal Health Inc | B- | $12.24B | — | 1.76 | Compare |
| CORT | Corcept Therapeutics Inc | C- | $12.07B | 218.66 | 0.50 | Compare |
| AXSM | Axsome Therapeutics Inc | B | $10.83B | — | 0.81 | Compare |
| CRNX | Crinetics Pharmaceuticals Inc | D+ | $9.01B | — | 0.45 | Compare |
| ZTS | Zoetis Inc | B | $31.87B | 11.97 | 0.69 | Compare |
| RPRX | Royalty Pharma PLC | A | $36.78B | 45.13 | 0.38 | Compare |
| MANE | Veradermics Inc | D- | $4.12B | — | -0.14 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. Three months free on iPhone.